

Financial news for XLRN dated on 2020-06-02: Citigroup Maintains Buy on Acceleron Pharma, Raises Price Target to \$137

Financial news for XLRN dated on 2020-05-20: Acceleron Announces Presentations On REBLOZYL (luspatercept-aamt) At 2020 American Society Of Clinical Oncology And European Hematology Association Virtual Annual Meetings

Financial news for XLRN dated on 2020-05-13: Acceleron Highlights Publication In Science Translational Medicine Showing Underlying Biology Behind Sotatercept's Potential As Novel Therapy In Pulmonary Arterial Hypertension

Financial news for XLRN dated on 2020-05-13: The Daily Biotech Pulse: Gilead Signs Manufacturing Deal For Remdesivir, Bristol-Myers Gets Refuse-To-File Letter

Financial news for XLRN dated on 2020-05-12: Stocks That Hit 52-Week Highs On Tuesday

Financial news for XLRN dated on 2020-05-12: JP Morgan Maintains Overweight on Acceleron Pharma, Raises Price Target to \$118

Financial news for XLRN dated on 2020-05-12: Oppenheimer Maintains Outperform on Acceleron Pharma, Raises Price Target to \$115

Financial news for XLRN dated on 2020-05-12: The Daily Biotech Pulse: NASH Disappointment For Genfit, Novavax Lands \$384M CEPI Funding For Coronavirus Vaccine, GW Pharma Earnings

Financial news for XLRN dated on 2020-05-11: Acceleron Pharma Q1 Net Loss \$50.9M, Sales \$4.300M Miss \$5.260M Estimate

Financial news for XLRN dated on 2020-05-10: The Week Ahead In Biotech: Virtual Conference Presentations, Clovis PDUFA Date In The Spotlight

Financial news for XLRN dated on 2020-05-08: Credit Suisse Maintains Outperform on Acceleron Pharma, Raises Price Target to \$123

Financial news for XLRN dated on 2020-05-08: The Daily Biotech Pulse: Ayala IPO, Pluristem Starts Phase 2 Trial Of COVID Treatment, European Nod For Takeda

Financial news for XLRN dated on 2020-05-07: Stocks That Hit 52-Week Highs On Thursday

Financial news for XLRN dated on 2020-05-04: 3 Keros Analysts On Why Biopharma Is A Compelling Investment Opportunity

Financial news for XLRN dated on 2020-05-04: Acceleron Receives Priority Medicines (PRIME) Designation From European Medicines Agency (EMA) For Sotatercept In Pulmonary Arterial Hypertension

Financial news for XLRN dated on 2020-04-30: Bristol Myers Squibb And Acceleron Receive Positive CHMP Opinion For The Treatment Of Adults With Anemia In Beta Thalassemia And Myelodysplastic Syndromes

Financial news for XLRN dated on 2020-04-21: Shares of several healthcare companies are trading lower with the overall market on continued downward momentum after oil prices fell to historic lows, partially stemming from weak demand caused by the coronavirus pandemic.

Financial news for XLRN dated on 2020-04-21: The Daily Biotech Pulse: Applied DNA Begins Validating COVID-19 Test, Cara's Positive Readout, Novan Explores Strategic Alternatives

Financial news for XLRN dated on 2020-04-15: The Daily Biotech Pulse: Applied DNA Ships Vaccine Constructs For Animal Testing, Herceptin Biosimilar Now Available In US

Financial news for XLRN dated on 2020-04-14: Stocks That Hit 52-Week Highs On Tuesday

Financial news for XLRN dated on 2020-04-08: The Daily Biotech Pulse: Genmark Pre-Announces Q1 Outperformance, Sage to Eliminate 53% of Workforce, Keros IPO

Financial news for XLRN dated on 2020-04-08: Acceleron Receives FDA Breakthrough Therapy Designation For Sotatercept In Pulmonary Arterial Hypertension

Financial news for XLRN dated on 2020-04-07: H.C. Wainwright Reiterates Buy on Acceleron Pharma, Raises Price Target to \$137

Financial news for XLRN dated on 2020-04-06: Oppenheimer Maintains Outperform on Acceleron Pharma, Raises Price Target to \$112

Financial news for XLRN dated on 2020-04-06: Benzinga's Top Upgrades, Downgrades For

April 6, 2020

Financial news for XLRN dated on 2020-04-06: Goldman Sachs Downgrades Acceleron Pharma to Sell, Announces \$73 Price Target

Financial news for XLRN dated on 2020-03-31: Attention Biotech Investors: Mark Your Calendar For These April PDUFA Dates

Financial news for XLRN dated on 2020-03-29: The Week Ahead In Biotech: Clinical Readouts, COVID-19 News Flow In Focus Amid Continuing Uncertainty

Financial news for XLRN dated on 2020-03-10: The Daily Biotech Pulse: Mesoblast To Test Candidate On Coronavirus Symptoms, Proxy Battle Ahead For Rockwell Medical, Glaukos to Join S&P SmallCap 600 Index

Financial news for XLRN dated on 2020-03-10: H.C. Wainwright Maintains Buy on Acceleron Pharma, Lowers Price Target to \$128

Financial news for XLRN dated on 2020-03-09: Acceleron Announces ACE-083 Did Not Achieve Statistically Significant Improvements In Functional Endpoints Relative To Placebo; Co. To Discontinue Development of ACE-083

Financial news for XLRN dated on 2020-03-04: The Daily Biotech Pulse: Takeda Jumps Into The COVID-19 Fray, Exact Sciences Buys Cancer Diagnostics Companies

Financial news for XLRN dated on 2020-03-03: Stocks That Hit 52-Week Highs On Tuesday

Financial news for XLRN dated on 2020-03-02: Citigroup Maintains Buy on Acceleron Pharma, Lowers Price Target to \$136

Financial news for XLRN dated on 2020-02-27: Acceleron Pharma Q4 EPS \$(0.44) Misses \$(0.3) Estimate, Sales \$39.338M Beat \$35.89M Estimate

Financial news for XLRN dated on 2020-02-27: Benzinga's Top Upgrades, Downgrades For February 27, 2020

Financial news for XLRN dated on 2020-02-27: Barclays Initiates Coverage On Acceleron Pharma with Overweight Rating, Announces \$107 Price Target

Financial news for XLRN dated on 2020-02-27: The Daily Biotech Pulse: Gilead Kicks Off Coronavirus Drug Trials, Adcom Nod For Lily, FDA Approves Esperion's Lipid-Lowering Adjunctive Combo Therapy

Financial news for XLRN dated on 2020-02-23: The Week Ahead In Biotech: Biopharma Earnings Pick Up Pace

Financial news for XLRN dated on 2020-02-18: H.C. Wainwright Maintains Buy on Acceleron Pharma, Raises Price Target to \$129

Financial news for XLRN dated on 2020-02-12: The Daily Biotech Pulse: J&J Intensifies Efforts On COVID-19 Cure, Adamas Reports Positive, Long-Term Gocovri Data

Financial news for XLRN dated on 2020-02-11: Stocks That Hit 52-Week Highs On Tuesday

Financial news for XLRN dated on 2020-02-11: Oppenheimer Maintains Outperform on Acceleron Pharma, Raises Price Target to \$112

Financial news for XLRN dated on 2020-02-07: The Daily Biotech Pulse: Assertio To Sell Opioid Pain Drug, Milestone Payment For Aduro, Myriad Genetics CEO Resigns

Financial news for XLRN dated on 2020-02-05: The Daily Biotech Pulse: Merck Spins Off Slow-Growth Businesses, ZioPharm Announces Offering, PhaseBio Data

Financial news for XLRN dated on 2020-02-04: Stocks That Hit 52-Week Highs On Tuesday

Financial news for XLRN dated on 2020-02-04: The Daily Biotech Pulse: EyePoint In-Licenses Eye Disorder Drug, BioMarin CFO Quits, Rockwell Medical To Offer Shares

Financial news for XLRN dated on 2020-02-03: Stocks That Hit 52-Week Highs On Monday

Financial news for XLRN dated on 2020-02-03: Benzinga's Top Upgrades, Downgrades For February 3, 2020

Financial news for XLRN dated on 2020-02-03: Acceleron Pharma shares are trading higher after Morgan Stanley upgraded the stock from Equal-Weight to Overweight and raised the price target from \$52 to \$122 per share.

Financial news for XLRN dated on 2020-02-03: Morgan Stanley Upgrades Acceleron Pharma to Overweight, Raises Price Target to \$122

Financial news for XLRN dated on 2020-02-02: The Week Ahead In Biotech: Merck, Bristol-Myers Earnings, Conference Presentations In Focus

Financial news for XLRN dated on 2020-01-31: Stocks That Hit 52-Week Highs On Friday

Financial news for XLRN dated on 2020-01-31: The Daily Biotech Pulse: Amgen Hurt By Generic Competition, Nanoviricides Confirms Working On Wuhan Virus, Arcutis IPO

Financial news for XLRN dated on 2020-01-31: 70 Biggest Movers From Yesterday

Financial news for XLRN dated on 2020-01-29: The Daily Biotech Pulse: Novartis Earnings, Hepion's NASH Candidate Beats Rival Drugs, Annovis Bio To Debut

Financial news for XLRN dated on 2020-01-29: Citigroup Maintains Buy on Acceleron Pharma, Raises Price Target to \$138

Financial news for XLRN dated on 2020-01-29: 70 Biggest Movers From Yesterday

Financial news for XLRN dated on 2020-01-28: Mid-Afternoon Market Update: Dow Surges 250 Points; Delphi Technologies Shares Gain On Acquisition News

Financial news for XLRN dated on 2020-01-28: Mid-Day Market Update: Crude Oil Rises Over 1%; Acceleron Pharma Shares Spike Higher

Financial news for XLRN dated on 2020-01-28: 46 Stocks Moving In Tuesday's Mid-Day Session

Financial news for XLRN dated on 2020-01-28: Stocks That Hit 52-Week Highs On Tuesday

Financial news for XLRN dated on 2020-01-28: Mid-Morning Market Update: Markets Open Higher; Pfizer Earnings Miss Views

Financial news for XLRN dated on 2020-01-28: Acceleron Hits All-Time High On Positive Readout For Pulmonary Arterial Hypertension Drug

Financial news for XLRN dated on 2020-01-28: 10 Biggest Price Target Changes For Tuesday

Financial news for XLRN dated on 2020-01-28: Piper Sandler Maintains Overweight on Acceleron Pharma, Raises Price Target to \$135

Financial news for XLRN dated on 2020-01-28: Goldman Sachs Reiterates Neutral on Acceleron Pharma, Raises Price Target to \$81

Financial news for XLRN dated on 2020-01-28: Credit Suisse Maintains Outperform on Acceleron Pharma, Raises Price Target to \$99

Financial news for XLRN dated on 2020-01-28: 10 Healthcare Stocks Moving In Tuesday's Pre-Market Session

Financial news for XLRN dated on 2020-01-28: 6 Biotechnology Stocks Moving In Tuesday's Pre-Market Session

Financial news for XLRN dated on 2020-01-28: 24 Stocks Moving in Tuesday's Pre-Market Session

Financial news for XLRN dated on 2020-01-28: The Daily Biotech Pulse: Acceleron's Positive Data Readout, Surface Oncology Gets Nod For Pushing 2 Antibodies Into Clinics

Financial news for XLRN dated on 2020-01-28: A Peek Into The Markets: US Stock Futures Up Ahead Of Earnings, Fed Meeting

Financial news for XLRN dated on 2020-01-28: Acceleron Pharma shares are trading higher after the company's Sotatercept achieved primary and secondary endpoints in the PULSAR Phase 2 trial in patients with pulmonary arterial hypertension.

Financial news for XLRN dated on 2020-01-27: 23 Biotechnology Stocks Moving In Monday's After-Market Session

Financial news for XLRN dated on 2020-01-27: 36 Healthcare Stocks Moving In Monday's After-Market Session

Financial news for XLRN dated on 2020-01-27: Acceleron Pharma shares are trading higher after the company announced Sotatercept achieved primary and secondary endpoints in PULSAR Phase 2 trial.

Financial news for XLRN dated on 2020-01-27: Acceleron Announces Sotatercept Achieved

Primary And Secondary Endpoints In PULSAR Phase 2 Placebo-Controlled Trial In Patients With Pulmonary Arterial Hypertension

Financial news for XLRN dated on 2020-01-22: Citigroup Maintains Buy on Acceleron Pharma, Raises Price Target to \$75

Financial news for XLRN dated on 2020-01-17: The Daily Biotech Pulse: Novo Nordisk's Ozempic Receives Label Expansion For Cardiovascular Events, Adcom Disappointment Inflicts Pain On Durect Shares

Financial news for XLRN dated on 2020-01-16: Stocks That Hit 52-Week Highs On Thursday

Financial news for XLRN dated on 2020-01-10: Stocks That Hit 52-Week Highs On Friday

Financial news for XLRN dated on 2020-01-10: The Daily Biotech Pulse: Positive Data Readouts To Spur Aclaris, Moderna And Ultragenyx

Financial news for XLRN dated on 2020-01-09: Stocks That Hit 52-Week Highs On Thursday

Financial news for XLRN dated on 2020-01-09: Bristol-Myers Squibb Highlights Publishing Of Results For Pivotal Phase 3 Reblozyl MEDALIST Trial In New England Journal Of Medicine

Financial news for XLRN dated on 2019-12-30: Acceleron And Fulcrum Therapeutics Announce Pulmonary Research And Discovery Collaboration Agreement; Fulcrum To Receive \$10M Upfront Payment And Milestones Of Up To \$295M For First Commercialized Product And Up To \$143.5M For Subsequent Products

Financial news for XLRN dated on 2019-12-20: Stocks That Hit 52-Week Highs On Friday

Financial news for XLRN dated on 2019-12-20: The Daily Biotech Pulse: Axovant Surges On Gene Therapy Study Results, FDA Approves Merck's Ebola Vaccine, Abeona Announces Offering

Financial news for XLRN dated on 2019-12-19: The Daily Biotech Pulse: Seattle Genetics' Bladder Cancer Drug Gets FDA Nod, Paratek Wins Contract For Antibiotic

Financial news for XLRN dated on 2019-12-18: Stocks That Hit 52-Week Highs On Wednesday

Financial news for XLRN dated on 2019-12-18: The Daily Biotech Pulse: Positive Adcom Verdict For Merck, Homology Medicine Slips On Mixed Gene Therapy Efficacy Data

Financial news for XLRN dated on 2019-12-17: Stocks That Hit 52-Week Highs On Tuesday

Financial news for XLRN dated on 2019-12-17: Morgan Stanley Maintains Equal-Weight on Acceleron Pharma, Raises Price Target to \$52

Financial news for XLRN dated on 2019-12-17: The Daily Biotech Pulse: Roche Gets US Antitrust Clearance For Spark Purchase, An Orphan Drug Designation For Prevail, Dynavax Names CEO

Financial news for XLRN dated on 2019-12-12: The Daily Biotech Pulse: European Nod For Amgen, miRagen Overhauls Clinical Pipeline, Tonix Snags Patent Win

Financial news for XLRN dated on 2019-12-11: Stocks That Hit 52-Week Highs On Wednesday

Financial news for XLRN dated on 2019-12-11: The Daily Biotech Pulse: Correvio Faces FDA Panel Rejection, Iterum's Antibiotic Trial Narrowly Misses Primary Endpoint

Financial news for XLRN dated on 2019-12-10: The Daily Biotech Pulse: ASH Meeting Wraps, Fast Track Designation For Equillium, Pfizer To Buy \$3M In ContraFect Shares

Financial news for XLRN dated on 2019-12-09: Bristol-Myers Reports Reblozyl Studies Evaluating Treatment Of Anemia In Rare Blood Diseases Presented At ASH

Financial news for XLRN dated on 2019-12-06: Bristol-Meyers Squibb And Acceleron Were Notified By FDA That Reblozyl Will Not Be Reviewed At Dec. 18 Oncologic Drugs Advisory Committee

Financial news for XLRN dated on 2019-12-03: Bristol-Myers Squibb And Acceleron Pharma Announce FDA Advisory Committee Will Review Reblozyl For Use In Patients With Myelodysplastic Syndromes

Financial news for XLRN dated on 2019-12-01: The Week Ahead In Biotech: ASH 2019 Gets Underway, Biogen's Aducanumab Data And More

Financial news for XLRN dated on 2019-11-07: 60 Biggest Movers From Yesterday

Financial news for XLRN dated on 2019-11-06: 62 Stocks Moving In Wednesday's Mid-Day Session

Financial news for XLRN dated on 2019-11-06: The Daily Biotech Pulse: Sesen Rallies On Positive FDA Meeting, Supernus Flunks Late-Stage ADHD Trial, GW Pharma Earnings

Financial news for XLRN dated on 2019-11-06: Acceleron Pharma Q3 EPS \$(0.86) Misses \$(0.82) Estimate, Sales \$4.21M Miss \$4.44M Estimate

Financial news for XLRN dated on 2019-10-11: Morgan Stanley Maintains Equal-Weight on Acceleron Pharma, Lowers Price Target to \$48

Financial news for XLRN dated on 2019-09-26: Shares of several healthcare companies are trading lower, potentially on recent Democratic primary polls showing Senator Elizabeth Warren in the lead.

Financial news for XLRN dated on 2019-09-24: Shares of many pharma/therapeutics stocks trading lower in sympathy with overall market weakness. Reports China is planning to cut prices for widely-used drugs may also be pressuring the sector today.

Financial news for XLRN dated on 2019-09-17: 10 Biggest Price Target Changes For Tuesday

Financial news for XLRN dated on 2019-09-17: 25 Stocks Moving in Tuesday's Pre-Market Session

Financial news for XLRN dated on 2019-09-17: Citi Maintains Buy on Acceleron Pharma, Lowers Price Target to \$52

Financial news for XLRN dated on 2019-09-17: The Daily Biotech Pulse: Acceleron Shelves Muscular Dystrophy Drug Trial, Aclaris Aces Late-Stage Study

Financial news for XLRN dated on 2019-09-17: Citigroup Maintains Buy on Acceleron Pharma, Lowers Price Target to \$52

Financial news for XLRN dated on 2019-09-16: Acceleron Pharma shares are trading lower after the company reported that its topline results from the Phase 2 trial of ACE-083 did not receive statistically significant improvements in functional endpoints.

Financial news for XLRN dated on 2019-09-16: Acceleron Reports Topline Results From Phase 2 Trial Of ACE-083 In Patients With Facioscapulohumeral Muscular Dystrophy: Did Not Achieve Statistically Significant Improvements In Functional Endpoints

Financial news for XLRN dated on 2019-09-09: Acceleron's Pulmonary Arterial Hypertension Asset Receives Orphan Drug Designation

Financial news for XLRN dated on 2019-09-09: Acceleron Receives FDA Orphan Drug Designation for Sotatercept in Pulmonary Arterial Hypertension

Financial news for XLRN dated on 2019-08-06: JP Morgan Maintains Overweight on Acceleron Pharma, Lowers Price Target to \$58

Financial news for XLRN dated on 2019-08-05: Acceleron Pharma Q2 EPS \$(0.34) Misses \$(0.29) Estimate, Sales \$27.666M Beat \$26.64M Estimate

Financial news for XLRN dated on 2019-08-03: The Week Ahead In Biotech: Focus On Earnings Deluge, Mid-Year Clinical Trial Readouts

Financial news for XLRN dated on 2019-07-11: Shares of several drug manufacturing companies are trading lower. The Trump Administration earlier rolled back a proposal to eliminate rebates from government drug plans and commented on continued efforts to lower drug prices.

Financial news for XLRN dated on 2019-07-08: Shares of several healthcare companies are trading lower after Trump said he was preparing an executive order declaring a 'favored nations clause' for drug prices, lowering the price that consumers will pay prescription drugs.

Financial news for XLRN dated on 2019-06-26: Acceleron Completes Target Enrollment In PULSAR Phase 2 Trial Of Sotatercept In Pulmonary Arterial Hypertension

Financial news for XLRN dated on 2019-06-10: Acceleron Pharma Reports Co-Founder Tom Maniatis To Retire

Financial news for XLRN dated on 2019-06-04: Celgene, Acceleron Pharma Report FDA

Acceptance Of Luspatercept Biologics License Application In Myelodysplastic Syndromes, Beta-Thalassemia

Financial news for XLRN dated on 2019-05-29: 5 Small-Cap Biotechs In Citi's Buy List With Big Upside Potential

Financial news for XLRN dated on 2019-05-29: Goldman Sachs Assumes Acceleron Pharma at Neutral, Announces Price Target \$54

Financial news for XLRN dated on 2019-05-24: Citigroup Assumes Acceleron Pharma Inc. - Common Stock at Buy

Financial news for XLRN dated on 2019-05-09: Acceleron Pharma Q1 EPS \$(0.74) Misses \$(0.59) Estimate, Sales \$2.78M Miss \$7.32M Estimate

Financial news for XLRN dated on 2019-05-09: The Daily Biotech Pulse: Novartis Goes Shopping, Mixed Trial Results For Provention Bio, 4 Stocks To Debut

Financial news for XLRN dated on 2019-05-03: Barclays Downgrades Acceleron Pharma Inc. - Common Stock to Equal-Weight, Lowers Price Target to \$45

Financial news for XLRN dated on 2019-04-30: Shares of several healthcare companies are trading lower on continued uncertainty over healthcare policy as well as concerns over the medicare-for-all proposals among 2020 candidates.

Financial news for XLRN dated on 2019-04-26: Celgene Corporation And Acceleron Pharma Announce Submission Of Luspatercept Marketing Authorization Application To European Medicines Agency For MDS And Beta-Thalassemia

Financial news for XLRN dated on 2019-04-22: Oppenheimer Assumes Acceleron Pharma at Outperform

Financial news for XLRN dated on 2019-04-09: Geron's Blood Cancer Candidate Creates Buying Opportunity, Needham Says In Upgrade

Financial news for XLRN dated on 2019-04-05: Celgene, Acceleron Reports Submission Of Luspatercept Biologics License Application To FDA

Financial news for XLRN dated on 2019-04-05: The Daily Biotech Pulse: Merrimack Pulls The Plug On Early-Stage Trial, Legal Headache For Novartis-Amgen Migraine Partnership

Financial news for XLRN dated on 2019-04-04: Acceleron Discontinues Development Of Phase 1 Molecule Ace-2494; Frequency Of Anti-Drug Antibodies Observed Among Participants In Study Has Led Co To Discontinue The Program

Financial news for XLRN dated on 2019-03-05: Acceleron Receives FDA Orphan Drug Designation For ACE-083 In Charcot-Marie-Tooth Disease

Financial news for XLRN dated on 2019-02-27: Acceleron Pharma Q4 EPS \$(0.75) Misses \$(0.68) Estimate, Sales \$3.82M Beat \$3.12M Estimate

Financial news for XLRN dated on 2019-02-26: Cowen & Co. Initiates Coverage On Acceleron Pharma with Outperform Rating, Announces \$78 Price Target

Financial news for XLRN dated on 2019-02-22: The Week Ahead In Biotech: Conferences, PDUFA Dates, Clinical Trials, Earnings, IPOs

Financial news for XLRN dated on 2019-02-01: 35 Stocks Moving In Friday's Pre-Market Session

Financial news for XLRN dated on 2019-01-16: Acceleron Prices ~5.35M Share Common Stock Offering At \$43/Share

Financial news for XLRN dated on 2019-01-16: 55 Biggest Movers From Yesterday

Financial news for XLRN dated on 2019-01-15: 40 Stocks Moving In Tuesday's Mid-Day Session

Financial news for XLRN dated on 2019-01-15: Acceleron Pharma shares are trading higher after the company reported a \$200 million common stock offering.

Financial news for XLRN dated on 2019-01-15: 24 Stocks Moving In Tuesday's Pre-Market Session

Financial news for XLRN dated on 2019-01-15: 10 Stocks To Watch For January 15, 2019

Financial news for XLRN dated on 2019-01-14: Acceleron Pharma shares are trading lower after the company announced a proposed \$200 million common stock offering.

Financial news for XLRN dated on 2019-01-14: Acceleron Reports \$200M Common Stock Offering

Financial news for XLRN dated on 2019-01-10: Acceleron Highlights Publication Of Luspatercept Phase 2 Beta-Thalassemia Study Results In Blood

Financial news for XLRN dated on 2019-01-08: 24 Stocks Moving In Tuesday's Pre-Market Session

Financial news for XLRN dated on 2018-12-02: Celgene, Acceleron Announce Phase 3 MEDALIST Trial Evaluating Luspatercept in Patients with Myelodysplastic Syndromes Presented at ASH 2018 Met The Primary Endpoint Of Red Blood Cell Transfusion Independence (RBC-TI) For 8 Or More Weeks During The First 24 Weeks Of The Study.

Financial news for XLRN dated on 2018-12-02: The Week Ahead In Biotech: ASH Presentations Pick Up Pace, PDUFA Dates, Clinical Trials And IPOs

Financial news for XLRN dated on 2018-12-02: Celgene, Acceleron Announce Phase 3 BELIEVE Trial Evaluating Luspatercept in Adult Patients with Beta-Thalassemia Met Primary Endpoint of Erythroid Response at ASH 2018

Financial news for XLRN dated on 2018-11-28: Acceleron Pharma Reports Fast Track Designation For ACE-083 For Charcot-Marie-Tooth Disease

Financial news for XLRN dated on 2018-11-25: The Week Ahead In Biotech: ASH 2018, PDUFA Dates, Clinical Trials And Earnings

Financial news for XLRN dated on 2018-11-01: Acceleron Announces To Present Phase 3 Results From MEDALIST And BELIEVE Trials Of Luspatercept At 60th American Society Of Hematology Annual Meeting Dec 1-4

Financial news for XLRN dated on 2018-10-30: Acceleron Q3 EPS \$(0.63) Beats \$(0.66) Estimate, Sales \$3.258M Miss \$3.9M Estimate

Financial news for XLRN dated on 2018-10-30: The Daily Biotech Pulse: Pfizer And Allergan Earnings, CFO Departures At Acadia And Assertio

Financial news for XLRN dated on 2018-10-27: The Week Ahead In Biotech: Conferences, PDUFA Dates, Clinical Trial Results, Earnings And IPOs

Financial news for XLRN dated on 2018-10-05: The Daily Biotech Pulse: MediciNova Gets Orphan-Drug Status, KemPharm To Offer Shares, Emergent Buys Vaccine Maker

Financial news for XLRN dated on 2018-09-24: Stocks Which Set New 52-Week High Friday, September 21

Financial news for XLRN dated on 2018-09-21: The Daily Biotech Pulse: Exelixis Liver Cancer Drug On Track For European Approval, Medtronic Goes Shopping, Opiant Snags BARDA Funding

Financial news for XLRN dated on 2018-09-21: Stocks Which Set New 52-Week High Yesterday, September 20th

Financial news for XLRN dated on 2018-09-20: Stocks Which Set New 52-Week High Yesterday, September 19th

Financial news for XLRN dated on 2018-09-20: The Daily Biotech Pulse: Adverum Snags Fast Track Designation, Crispr To Offer Shares, Elanco Animal Health To Debut

Financial news for XLRN dated on 2018-09-18: Analyst: Acceleron's Blood Disorder Candidate Luspatercept Has Blockbuster Potential

Financial news for XLRN dated on 2018-09-18: 10 Biggest Price Target Changes For Tuesday

Financial news for XLRN dated on 2018-09-18: Benzinga's Top Upgrades, Downgrades For September 18, 2018

Financial news for XLRN dated on 2018-09-18: PiperJaffray Upgrades Acceleron Pharma to Overweight, Raises Price Target to \$75

Financial news for XLRN dated on 2018-09-10: Morgan Stanley Assumes Acceleron Pharma at Equal-Weight, Announces Price Target \$55

Financial news for XLRN dated on 2018-09-04: Stocks Which Set New 52-Week High Friday, August 31

Financial news for XLRN dated on 2018-08-31: Stocks Which Set New 52-Week High Yesterday, August 30th

Financial news for XLRN dated on 2018-08-31: The Daily Biotech Pulse: FDA Blessings for Merck's HIV Drug Combo, Veracyte's Test Gets Medicare Coverage

Financial news for XLRN dated on 2018-08-30: Stocks Which Set New 52-Week High Yesterday, August 29th

Financial news for XLRN dated on 2018-08-30: The Daily Biotech Pulse: Verastem Gets New CFO, Mesoblast Earnings, Vertex's Precision Medicine Collaboration

Financial news for XLRN dated on 2018-08-29: Stocks Which Set New 52-Week High Yesterday, August 28th

Financial news for XLRN dated on 2018-08-27: Stocks Which Set New 52-Week High Friday, August 24th

Financial news for XLRN dated on 2018-08-14: 13F From Omega Shows Exited Stake In Acceleron Pharma, Xencor and Shell Midstream Partners

Financial news for XLRN dated on 2018-08-03: The Daily Biotech Pulse: Zafgen Executive Departs; Adamas, Acceleron Accelerate On Earnings

Financial news for XLRN dated on 2018-08-02: Acceleron Pharma Q2 EPS \$(0.63) Beats \$(0.64) Estimate, Sales \$3.69M Miss \$3.8M Estimate

Financial news for XLRN dated on 2018-08-02: The Daily Biotech Pulse: Denali's Parkinson's Candidate Clears Early-Stage Trials, Dexcom's Strong Quarter

Financial news for XLRN dated on 2018-08-02: Acceleron Pharma Q2 Earnings Preview

Financial news for XLRN dated on 2018-07-31: Acceleron Pharma Option Alert: Aug 17 \$50 Calls at the Ask: 3000 @ \$0.201 vs 3933 OI; Earnings 8/2 After Close Ref=\$42.0

Financial news for XLRN dated on 2018-07-28: The Week Ahead In Biotech: Conferences, PDUFA Dates, Earnings And IPOs

Financial news for XLRN dated on 2018-07-23: Acceleron Announces Preliminary Results from Part 1 of the ACE-083 Phase 2 Trial in Patients with Charcot-Marie-Tooth Disease

Financial news for XLRN dated on 2018-07-13: Morgan Stanley Downgrades Acceleron As Valuation Reaches Price Target

Financial news for XLRN dated on 2018-07-13: Benzinga's Top Upgrades, Downgrades For July 13, 2018

Financial news for XLRN dated on 2018-07-13: Morgan Stanley Downgrades Acceleron Pharma to Equal-Weight

Financial news for XLRN dated on 2018-07-12: Acceleron Receives FDA Orphan Drug Designation for ACE-083 in Facioscapulohumeral Muscular Dystrophy

Financial news for XLRN dated on 2018-07-10: PiperJaffray Downgrades Acceleron Pharma to Neutral

Financial news for XLRN dated on 2018-07-10: Benzinga's Daily Biotech Pulse: Acceleron On Fast Lane, OncoCyte's Accurate Diagnosis, Inspire Medical Gets Aetna Coverage

Financial news for XLRN dated on 2018-07-10: 20 Stocks Moving In Tuesday's Pre-Market Session

Financial news for XLRN dated on 2018-07-09: Acceleron Pharma Shares Up 11.6% After Co. Achieved Primary And All Key Secondary Endpoints In Phase III 'BELIEVE' Study Of Luspatercept With Celgene

Financial news for XLRN dated on 2018-07-09: Celgene And Acceleron Announce Luspatercept Achieved Primary And All Key Secondary Endpoints In Phase III 'BELIEVE' Study In Adults With Transfusion-Dependent Beta-Thalassemia; Regulatory Submissions Planned In US And Europe In 1H 2019

Financial news for XLRN dated on 2018-07-08: The Week Ahead In Biotech: Conferences, PDUFA Dates And Clinical Trials

Financial news for XLRN dated on 2018-07-05: Acceleron Pharma Names Robert Zeldin Chief Medical Officer

Financial news for XLRN dated on 2018-07-02: 44 Biggest Movers From Friday

Financial news for XLRN dated on 2018-06-29: Mid-Afternoon Market Update: Echelon



Climbs On Acquisition News; InspireMD Shares Slide

Financial news for XLRN dated on 2018-06-29: 35 Stocks Moving In Friday's Mid-Day Session

Financial news for XLRN dated on 2018-06-29: Mid-Day Market Update: Crude Oil Up Over 1%; Gemphire Therapeutics Shares Spike Higher

Financial news for XLRN dated on 2018-06-29: Acceleron Pharma Rallies After Phase 3 MDS Data, But Goldman Sachs Still Isn't Buying

Financial news for XLRN dated on 2018-06-29: 'The success of \$XLRN luspatercept is bad for \$GERN and another reason for \$JNJ to sever the imetelstat relationship in Q3.'-STAT's Adam Feuerstein Tweets

Financial news for XLRN dated on 2018-06-29: 10 Biggest Price Target Changes For Friday

Financial news for XLRN dated on 2018-06-29: Benzinga's Top Upgrades, Downgrades For June 29, 2018

Financial news for XLRN dated on 2018-06-29: Benzinga's Daily Biotech Pulse: Gemphire On Fire, Acceleron-Celgene Taste Success, AbbVie Ditches Galapagos

Financial news for XLRN dated on 2018-06-29: Goldman Sachs Upgrades Acceleron Pharma to Neutral, Raises Price Target to \$40

Financial news for XLRN dated on 2018-06-28: Celgene, Acceleron Announce Luspatercept Achieved Primary and Key Secondary Endpoints in Phase III 'MEDALIST' Study

Financial news for XLRN dated on 2018-06-26: Acceleron To Present Preliminary Data On ACE-083 At 2018 Annual Meeting Of The Peripheral Nerve Society July 22-25

Financial news for XLRN dated on 2018-06-15: UPDATE: Acceleron Says Of Transfusion-Dependent Patients, '41% (12 of 29) achieved a reduction in RBC transfusion burden of at least 33% in the fixed 12-week intervals including weeks 13-24, 37-48 when compared to baseline'

Financial news for XLRN dated on 2018-06-15: UPDATE: Acceleron On Luspatercept Results: 'At week 48, the mean improvement in 6-minute walk distance was 18.6% compared to baseline'

Financial news for XLRN dated on 2018-06-15: Acceleron Offers Updated Results From Ongoing Phase 2 Trials Of Luspatercept In Patients With Beta-Thalassemia, Showed 51% (16 Of 30) Patients Achieved  $\geq 1$  gram per deciliter increase in hemoglobin in the fixed 12-week intervals including weeks 13-24'

Financial news for XLRN dated on 2018-06-05: Acccleron Option Alert: Aug 17 \$45 Calls at the Ask: 800 @ \$5.201 vs 1205 OI; Earnings 8/2 After Close [est] Ref=\$36.71

Financial news for XLRN dated on 2018-06-04: Acceleron Announces Updated Results from Ongoing Phase 2 Trials of Luspatercept in Myelodysplastic Syndromes at the ASCO 2018 Annual Meeting

Financial news for XLRN dated on 2018-06-03: The Week Ahead In Biotech: ASCO Presentations Dominate The Headlines

Financial news for XLRN dated on 2018-05-22: UBS Global Healthcare Conference 2018 Continues Today, Presenters Include: Civitas Solutions, Revance, Akebia Therapeutics, Bristol-Myers, Senseonics, Lantheus, Acceleron Pharma, and HCA Healthcare

Financial news for XLRN dated on 2018-05-22: Acceleron Announces Initiation Of PULSAR Phase 2 Trial Of Sotatercept In Pulmonary Arterial Hypertension

Financial news for XLRN dated on 2018-05-21: SMid-Cap Biotech: Barclays Downgrades Prothena, Upgrades Achillion

Financial news for XLRN dated on 2018-05-08: Acceleron Pharma Q1 EPS \$(0.58) Beats \$(0.64) Estimate, Sales \$3.232M Miss \$4.21M Estimate

Financial news for XLRN dated on 2018-05-08: Benzinga's Daily Biotech Pulse: Valeant Earnings, Lipocine's FDA Watch, Invivo CFO Departure

Financial news for XLRN dated on 2018-05-01: Acceleron Receives FDA Fast Track Designation for ACE-083 in Facioscapulohumeral Muscular Dystrophy

Financial news for XLRN dated on 2018-03-01: Citigroup Maintains Buy on Acceleron Pharma, Raises Price Target to \$63.00

Financial news for XLRN dated on 2018-02-28: Barclays Maintains Overweight on Acceleron Pharma, Raises Price Target to \$54.00

Financial news for XLRN dated on 2018-02-28: Acceleron Reports Publication Of ACE-083 Phase I Trial Results In Journal 'Muscle & Nerve': 'treatment generated dose-dependent mean total muscle volume increases of up to 14.5% in the RF, 8.9% in the TA three weeks after last dose'

Financial news for XLRN dated on 2018-02-27: Acceleron Reports Q4 EPS \$(0.62) vs \$(0.51) In Same Qtr. Last Year, Sales \$3.705M

Financial news for XLRN dated on 2018-02-27: 38 Biggest Movers From Yesterday

Financial news for XLRN dated on 2018-02-26: 28 Stocks Moving In Monday's Mid-Day Session

Financial news for XLRN dated on 2018-02-26: Benzinga's Top Upgrades, Downgrades For February 26, 2018

Financial news for XLRN dated on 2018-02-26: JP Morgan Upgrades Acceleron Pharma to Overweight

Financial news for XLRN dated on 2018-02-25: The Week Ahead In Biotech: Earnings, PDUFA Dates And More

Financial news for XLRN dated on 2018-01-08: UPDATE: Acceleron Says Co. Planning To Initiate Part 2 Of FSHD Phase 2 Trial In Q2'18

Financial news for XLRN dated on 2018-01-08: UPDATE: Acceleron Says 'Mean total muscle volume increases of over 12% in the tibialis anterior and biceps brachii muscle cohorts'

Financial news for XLRN dated on 2018-01-08: Acceleron Pharma Reports Prelim. Results From Part 1 Of ACE-083 Phase 2 Trial In Patients With Facioscapulohumeral Dystrophy

Financial news for XLRN dated on 2018-01-08: Acceleron Announces Prelim Results For Phase 2 Trial Of ACE-083 Demonstrate Positive Safety Profile, Co. Will Initiate Part 2 Of Trial In Q2

Financial news for XLRN dated on 2018-01-03: Acceleron Announces Planned Retirement of Chief Medical Officer, Dr. Matthew L. Sherman

Financial news for XLRN dated on 2017-12-10: Acceleron Announces Updated Results from Ongoing Phase 2 Trials of Luspatercept in Myelodysplastic Syndromes at #ASH2017

Financial news for XLRN dated on 2017-12-08: REMINDER: ASH Meeting Begins Tomorrow Dec. 9, Presenters Include Bellicum Pharmaceuticals, Affimed, Cellectis (Pediatric Data for UCART19), and Acceleron Pharma

Financial news for XLRN dated on 2017-11-14: Acceleron Announces Preclinical Results For TGF-beta Therapy

Financial news for XLRN dated on 2017-11-14: 13F Filing From Baker Bros Shows Increased Stake In Acceleron Pharma, New Stake In Acorda Therapeutics

Financial news for XLRN dated on 2017-11-14: Credit Suisse Maintains Outperform on Acceleron Pharma, Raises Price Target to \$51.00

Financial news for XLRN dated on 2017-11-07: Acceleron Pharma Reports Q3 EPS \$(0.65) vs \$(0.64) Est., Sales \$3.01M vs \$4.8M Est.

Financial news for XLRN dated on 2017-10-12: 4 Biotech Stocks Initiated At Buy: Acceleron, Tesaro, Mirati, Fate

Financial news for XLRN dated on 2017-10-12: Benzinga's Top Upgrades, Downgrades For October 12, 2017

Financial news for XLRN dated on 2017-10-12: H.C. Wainwright Initiates Coverage On Acceleron Pharma with Buy Rating, Announces \$57.00 Price Target

Financial news for XLRN dated on 2017-09-21: Mid-Afternoon Market Update: Scholastic Falls After Q1 Results; Akari Therapeutics Shares Surge

Financial news for XLRN dated on 2017-09-21: 12 Biggest Mid-Day Losers For Thursday

Financial news for XLRN dated on 2017-09-19: Acceleron Reports Offering Of \$150M In Common Stock

Financial news for XLRN dated on 2017-09-19: Acceleron Pharma and Celgene Enter Into

Amended Collaboration, License and Option Agreement Originally Dated Feb 20, 2008

Financial news for XLRN dated on 2017-09-15: RBC Initiated Coverage On 33  
Pharma/Biotech Cos.

Financial news for XLRN dated on 2017-08-03: Acceleron Pharma Reports Q2 EPS \$(0.77)  
vs \$(0.63) Est., Sales \$3.05M vs \$3.69M Est.

Financial news for XLRN dated on 2017-08-01: Acceleron Announces First Patient  
Treated in Phase 2 Clinical Trial of ACE-083 in Charcot-Marie-Tooth Disease

Financial news for XLRN dated on 2017-06-23: Acceleron Provides Updated Results from  
Ongoing Phase 2 Study of Luspatercept in Myelodysplastic Syndromes #EHA2017

Financial news for XLRN dated on 2017-06-23: Acceleron Provides Updated Results from  
Phase 2 Studies of Luspatercept in Beta-Thalassemia #EHA2017

Financial news for XLRN dated on 2017-06-13: Benzinga's Top Upgrades, Downgrades For  
June 13, 2017

Financial news for XLRN dated on 2017-06-13: 25 Stocks Moving In Tuesday's Pre-Market  
Session

Financial news for XLRN dated on 2017-06-13: Oppenheimer Downgrades Acceleron Pharma  
to Market Perform

Financial news for XLRN dated on 2017-06-12: UPDATE: Acceleron Announces Will  
Discontinue Development Of Dalantercept

Financial news for XLRN dated on 2017-06-12: Acceleron Offers Results From DART Phase  
2 Study Of Dalantercept In Advanced Renal Cell Carcinoma: Did Not Achieve Primary  
Endpoint

Financial news for XLRN dated on 2017-05-17: Benzinga's Top Upgrades, Downgrades For  
May 17, 2017

Financial news for XLRN dated on 2017-05-17: Goldman Sachs Initiates Coverage On  
Acceleron Pharma with Sell Rating, Announces \$20.00 Price Target

Financial news for XLRN dated on 2017-05-08: Acceleron Pharma Q1 EPS \$(0.66) vs  
\$(0.54) Est., Sales \$3.71M vs \$3.91M Est

Financial news for XLRN dated on 2017-05-02: Acceleron Pharma Reports Steven Ertel To  
Transition From COO To Special Advisor To The CEO

Financial news for XLRN dated on 2017-04-27: UPDATE: Acceleron Announces Co., Celgene  
Will Initiate Added Phase 3 Trial in MDS in Early '18

Financial news for XLRN dated on 2017-04-27: Acceleron Announces 'Enrollment in  
MEDALIST and BELIEVE Phase 3 studies now expected to be completed in Q2 2017'

Financial news for XLRN dated on 2017-03-16: UPDATE: Acceleron Says Second Phase 2  
Study for ACE-083 Expected to Begin 2H'17

Financial news for XLRN dated on 2017-03-16: Acceleron Pharma Reports Plan to  
Initiate Phase 2 Trial of ACE-083 in Charcot-Marie-Tooth Neuromuscular Disease

Financial news for XLRN dated on 2017-03-14: Benzinga's Top Upgrades, Downgrades For  
March 14, 2017

Financial news for XLRN dated on 2017-03-14: JP Morgan Initiates Coverage On  
Acceleron Pharma With Neutral, Announces \$33 Price Target

Financial news for XLRN dated on 2017-03-09: UBS Initiates Coverage On Acceleron  
Pharma With Buy, Announces \$36 Price Target

Financial news for XLRN dated on 2017-03-02: 25 Biggest Mid-Day Gainers For Thursday

Financial news for XLRN dated on 2017-03-02: Benzinga's Top Upgrades, Downgrades For  
March 2, 2017

Financial news for XLRN dated on 2017-03-02: Nomura Initiates Coverage On Acceleron  
Pharma at Buy

Financial news for XLRN dated on 2017-03-02: Citigroup Upgrades Acceleron Pharma to  
Buy, Lowers Price Target to \$36.00

Financial news for XLRN dated on 2017-03-01: Acceleron Reports Q4 EPS \$(0.51) vs  
\$(0.55) Est., Sales \$3.369M vs \$3.7M Est.

Financial news for XLRN dated on 2017-01-09: TheStreet's Adam Feuerstein Tweets '\$CELG spending a lot of time talking up pipeline from partners. \$BLUE \$XLRN etc. #JPM17'

Financial news for XLRN dated on 2017-01-06: Acceleron Outlines 2017 Timeline

Financial news for XLRN dated on 2016-12-13: Oppenheimer Earlier Initiated Coverage On Acceleron Pharma at Outperform

Financial news for XLRN dated on 2016-12-05: What Is The ASH Conference And Why Should Biotech Investors Care?

Financial news for XLRN dated on 2016-12-04: Acceleron, Celgene Announce Updated Results from Ongoing Phase 2 Studies of Luspatercept in Myelodysplastic Syndromes at ASH 2016

Financial news for XLRN dated on 2016-12-02: American Society Of Hematology Meeting Begins Dec. 3rd, Day 1 of 4

Financial news for XLRN dated on 2016-11-17: Acceleron Pharma Block Of 450K Shares Trading At UBS, Price \$38.50

Financial news for XLRN dated on 2016-11-03: Acceleron Pharma Reports Q3 EPS \$(0.55) vs. Est. \$(0.53), Rev. \$3.005M vs. \$4.08M

Financial news for XLRN dated on 2016-09-29: Citigroup Initiates Coverage on Acceleron Pharma at Neutral, Announces \$40.00 PT

Financial news for XLRN dated on 2016-09-27: Acceleron Announces John Knopf To Retire As CEO, Habib Dable Named Successor Effective Dec 1

Financial news for XLRN dated on 2016-09-15: 20 Stocks Which Rallied Three Days

Financial news for XLRN dated on 2016-08-19: Benzinga's Top Initiations

Financial news for XLRN dated on 2016-08-19: Acceleron Has 2 Phase III Trials With Good Chance Of Success; BTIG Initiates Stock At Buy

Financial news for XLRN dated on 2016-08-19: BTIG Research Initiates Coverage on Acceleron Pharma at Buy, Announces \$46.00 PT

Financial news for XLRN dated on 2016-08-04: Acceleron Pharma Reports Q2 EPS \$(0.59) vs. Est. \$(0.50), Rev. \$3.195M vs. Est. \$3.77M

Financial news for XLRN dated on 2016-07-08: Acceleron Reports ACE-083 Phase 1 Results at the 14th International Congress on Neuromuscular Diseases

Financial news for XLRN dated on 2016-06-23: Analysts Confident In Acceleron Pharma's Drug Trial Outcomes

Financial news for XLRN dated on 2016-06-13: Acceleron's Luspatercept Is All About Duration, And This Analyst Is Excited About Its Prospects

Financial news for XLRN dated on 2016-06-13: Barclays Raises Acceleron Price Target On Positive Luspatercept Data

Financial news for XLRN dated on 2016-06-10: Acceleron, Celgene Offer Updated Results from Ongoing Phase 2 Study of Luspatercept

Financial news for XLRN dated on 2016-05-05: Acceleron Reports Q1 EPS \$0.13 vs \$(0.45) in Same Qtr. Last Year, Sales \$18.2M

Financial news for XLRN dated on 2016-04-27: Barclays Initiates Coverage on Acceleron Pharma at Overweight, Announces \$40.00 PT

Financial news for XLRN dated on 2016-02-29: Janney: Time To Buy Acceleron

Financial news for XLRN dated on 2016-02-29: Benzinga's Top Upgrades

Financial news for XLRN dated on 2016-02-29: Janney Capital Upgrades Acceleron Pharma to Buy

Financial news for XLRN dated on 2016-02-25: Acceleron Pharma Reports Q4 EPS \$(0.81) vs \$(0.55) in Same Qtr. Last Year, Sales \$3.804M vs \$3.739M YoY

Financial news for XLRN dated on 2016-02-25: Acceleron Pharma Reports Q4 EPS \$(0.81) vs \$(0.55) in Same Qtr. Last Year, Sales \$3.804M vs \$3.739M YoY

Financial news for XLRN dated on 2016-02-01: Oppenheimer Assumes Acceleron Pharma at Outperform

Financial news for XLRN dated on 2016-02-01: Oppenheimer Assumes Acceleron Pharma at Outperform

Financial news for XLRN dated on 2016-01-21: The Street Might Be Discounting A Potential Blockbuster Drug From Acceleron

Financial news for XLRN dated on 2016-01-20: Credit Suisse Initiates Coverage on Acceleron Pharma at Outperform, Announces \$50.00 PT

Financial news for XLRN dated on 2016-01-11: 13D Filing Shows Acceleron Pharma Sells 800K Shares To Celgene

Financial news for XLRN dated on 2016-01-05: Acceleron Prices 3.75M Share Offering @\$40.00/Share

Financial news for XLRN dated on 2016-01-04: Acceleron Reports Offering of \$150M in Common Shares

Financial news for XLRN dated on 2016-01-04: Filing from Acceleron Pharma Shows Registration for \$300M Common Stock Offering

Financial news for XLRN dated on 2015-12-09: Adam Feuerstein @adamfeuerstein Tweet \$XLRN only positive data I saw at #ASH15

Financial news for XLRN dated on 2015-12-07: Celgene, Acceleron Offer New Results from Study with Luspatercept in Beta-Thalassemia at ASH

Financial news for XLRN dated on 2015-12-07: FDA Fast Track Designation Granted to Luspatercept for the Treatment of Patients with Lower-Risk Myelodysplastic Syndromes

Financial news for XLRN dated on 2015-12-05: Celgene, Acceleron Announce New Results from Study with Luspatercept in Myelodysplastic Syndromes Presented at #ASH2015

Financial news for XLRN dated on 2015-12-01: Acceleron Reports Oral Plenary Presentation for ACE-083 in Late-Breaking Trial

Financial news for XLRN dated on 2015-11-20: Benzinga's Top Initiations

Financial news for XLRN dated on 2015-11-20: Oppenheimer Initiates Coverage on Acceleron Pharma at Outperform

Financial news for XLRN dated on 2015-11-04: Acceleron Pharma Reports Q3 Loss of \$0.36/Share vs Loss of \$0.46/Share Est.

Financial news for XLRN dated on 2015-10-23: Acceleron Highlights Phase 3 Studies, New Clinical Results and Research Strategies at Research and Development Day Event

Financial news for XLRN dated on 2015-10-06: Leerink Chats With Biotech Management, Names 20 Stocks To Buy Now

Financial news for XLRN dated on 2015-10-01: Acceleron Presents Preclinical Data for ACE-083 and ACE-2494 at the 20th International Annual Congress of the World Muscle Society

Financial news for XLRN dated on 2015-08-27: Acceleron Pharma 13D Shows Holder Polaris Holds 4.5% Stake As Of Aug. 17, Now Holds 1.454M Shares Down From 1.887M Shares

Financial news for XLRN dated on 2015-08-13: Morgan Stanley Initiates Coverage on Acceleron Pharma at Overweight, Announces \$50.00 PT

Financial news for XLRN dated on 2015-08-06: Acceleron Pharma Reports Q2 EPS \$(0.32) vs. Est. \$(0.49), Rev. \$5.717M vs. Est. \$4.23M

Financial news for XLRN dated on 2015-06-15: JMP Sees A 'Negative Market Tone' In Biotechnology

Financial news for XLRN dated on 2015-06-15: Acceleron Reports Publication in Cancer Research Dalantercept Prevents Metastases in Preclinical Studies of Breast Cancer

Financial news for XLRN dated on 2015-06-12: Acceleron Announces New Luspatercept Phase 2 Clinical Results at the 20th Congress of the European Hematology Association

Financial news for XLRN dated on 2015-06-10: Watch How These 10 Stocks Respond Today

Financial news for XLRN dated on 2015-06-09: Guggenheim Securities Initiates Coverage

on Acceleron Pharma at Neutral

Financial news for XLRN dated on 2015-05-18: Celgene, Acceleron Pharma Announces FDA Fast Track Designation for Luspatercept for Treatment of Patients with Beta-Thalassemia

Financial news for XLRN dated on 2015-05-07: Acceleron Pharma. Reports Q1 EPS \$(0.45) vs. Est. \$(0.45), Rev. \$4.420M vs. Est. \$4.27M

Financial news for XLRN dated on 2015-03-06: Acceleron Pharma Appoints Steven Ertel EVP, COO and Matthew Sherman M.D. Promoted To EVP, Chief Medical Officer

Financial news for XLRN dated on 2015-03-02: Acceleron Pharma Reports Q4 EPS -\$0.55 Vs Est. -\$0.23

Financial news for XLRN dated on 2015-02-24: Why JMP Securities Is Watching (And Loving) These 3 Biotech Stocks

Financial news for XLRN dated on 2014-12-31: 19 Lesser-Known Biotech Stocks With Robust Drug Pipelines

Financial news for XLRN dated on 2014-12-08: Mid-Afternoon Market Update: Dow Slides Over 100 Points; Oil Futures Down 4%

Financial news for XLRN dated on 2014-12-08: Celgene, Acceleron Pharma Report Prelim. Data from Ongoing Phase 2 Trials in Patients with Lower Risk MDS:: Luspatercept, Sotatercept Increased Hemoglobin Levels

Financial news for XLRN dated on 2014-12-08: Mid-Day Gainers From December 8: Cubist Pharmaceuticals, Acceleron Pharma, Calithera Biosciences, Cempira, Isis Pharmaceuticals

Financial news for XLRN dated on 2014-12-08: Mid-Day Market Update: McDonald's Drops On Weak November Sales; Acceleron Pharma Shares Jump

Financial news for XLRN dated on 2014-12-08: Mid-Morning Market Update: Markets Mixed; Merck To Buy Cubist Pharmaceuticals For \$102/Share

Financial news for XLRN dated on 2014-12-08: Stocks Hitting 52-Week Highs

Financial news for XLRN dated on 2014-12-08: Morning Market Movers

Financial news for XLRN dated on 2014-12-08: Benzinga's Top #PreMarket Gainers

Financial news for XLRN dated on 2014-12-07: Celgene, Acceleron Present New Data from Luspatercept Phase 2 Clinical Trial in Beta-Thalassemia at ASH Annual Meeting

Financial news for XLRN dated on 2014-11-13: Acceleron Pharma Inc. Announces Sotatercept Data from the Phase 2a Clinical Trial in Hemodialysis Patients Presented at the American Society of Nephrology Kidney Week 2014

Financial news for XLRN dated on 2014-11-07: Acceleron Reports Q3 EPS of \$(0.25) vs \$(0.42) Est

Financial news for XLRN dated on 2014-10-14: Acceleron Initiates Phase 1 Clinical Trial With Innovative Muscle Drug ACE-083

Financial news for XLRN dated on 2014-09-23: Acceleron Offers Update on Externally-Sponsored Clinical Trial of Dalantercept Monotherapy in Ovarian Cancer

Financial news for XLRN dated on 2014-08-14: FBR Capital Initiates Coverage on Acceleron at Outperform, Announces \$47.00 PT

Financial news for XLRN dated on 2014-08-14: Leerink Swann Initiates Coverage on Acceleron at Outperform, Announces \$57.00 PT

Financial news for XLRN dated on 2014-08-12: Acceleron Reports Q2 EPS of \$(0.52) vs \$(0.45) Est

Financial news for XLRN dated on 2014-06-23: Events Scheduled for Week of Jun 23rd to Jun 27th, 2014

Financial news for XLRN dated on 2014-05-15: Acceleron Reports Q1 EPS of \$(0.30) vs \$(0.44) Est; Revenue of \$3.31M vs \$2.85M Est

Financial news for XLRN dated on 2014-05-14: Acceleron To Report Encouraging Clinical Data From Phase 2 Dalantercept at American Society of Oncology June 2

Financial news for XLRN dated on 2014-04-02: Mid-Day Market Update: Apollo Drops

After Q2 Results; MannKind Shares Spike Higher

Financial news for XLRN dated on 2014-04-02: Mid-Morning Market Update: Markets Flat; Monsanto Earnings Beat Street View

Financial news for XLRN dated on 2014-04-02: Morning Market Movers

Financial news for XLRN dated on 2014-04-02: Form 8-K Acceleron Pharma Shows Celgene to Buy 1.1M Shares for \$47.15M

Financial news for XLRN dated on 2014-01-28: Acceleron Pharma Announces Closing of Offering, Reports Full Exercise of Overallotment Options by Underwriters, Expecting Proceeds of ~\$129M

Financial news for XLRN dated on 2014-01-23: Benzinga's Top #PreMarket Losers

Financial news for XLRN dated on 2014-01-22: Acceleron Prices 2.4M Share Offering at \$50.00/Share

Financial news for XLRN dated on 2014-01-21: US Stock Futures Signal Higher Start On Wall Street

Financial news for XLRN dated on 2014-01-21: Acceleron Commences \$100M Offering of Common Stock

Financial news for XLRN dated on 2014-01-03: 15 Notable IPOs of 2013: Investment Idea of the Day

Financial news for XLRN dated on 2013-12-18: Acceleron Earns \$7M Milestone Payment f Celgene

Financial news for XLRN dated on 2013-12-12: UPDATE: JMP Securities Reiterates on Acceleron Pharma on Elevated Confidence

Financial news for XLRN dated on 2013-12-12: JMP Securities Maintains Market Outperform on Acceleron, Raises PT to \$36.00

Financial news for XLRN dated on 2013-12-09: Acceleron, Celgene Report New Interim Clinical Data from Phase 2 Trial of Sotatercept in Beta-Thalassemia at ASH

Financial news for XLRN dated on 2013-12-02: Acceleron Announces Presentation of New Interim Phase 2 Sotatercept Clinical Data in Beta-Thalassemia

Financial news for XLRN dated on 2013-11-06: Acceleron Reports Q3 EPS of \$(5.62) Which May Not Compare \$(0.40) Est

Financial news for XLRN dated on 2013-10-14: UPDATE: Piper Jaffray Initiates Coverage on Acceleron Pharma on Promising Anemia and Cancer Play

Financial news for XLRN dated on 2013-10-14: Benzinga's Top Initiations

Financial news for XLRN dated on 2013-10-14: Citigroup Initiates Coverage on Acceleron at Buy, Announces \$30.00 PT

Financial news for XLRN dated on 2013-10-14: Leerink Swann Initiates Coverage on Acceleron at Outperform, Announces \$33.00 PT

Financial news for XLRN dated on 2013-10-14: JMP Securities Initiates Coverage on Acceleron at Market Outperform, Announces \$32.00 PT

Financial news for XLRN dated on 2013-10-14: Piper Jaffray Initiates Coverage on Acceleron at Overweight, Announces \$32.00 PT

Financial news for XLRN dated on 2013-09-19: Shares of Acceleron Pharma Open at \$18.50 After Pricing at \$15, Stock Now Up to \$19.35

Financial news for XLRN dated on 2013-09-19: IPO for Acceleron Pharma to Open for Trade at 10:40AM EDT, Quotes Opened as of 10:25AM; Co. Priced 5.58M Shares at \$15/Share

Financial news for XLRN dated on 2013-09-18: Acceleron Prices 5.58M Share IPO at \$15.00/Share